MDT Medtronic Plc

Medtronic Surgical Synergy(SM) is Advanced with Range of New Procedural Solutions Unveiled at NASS 2019

Medtronic Surgical Synergy(SM) is Advanced with Range of New Procedural Solutions Unveiled at NASS 2019

Delivers the Industry’s Most Complete Portfolio of Implants, Biologics, Imaging, Navigation, Robotics, and Surface Technologies Designed to Transform Spine Outcomes

Marks Milestone Surpassing 1,000 Mazor X Stealth Edition™ Robotic-Assisted Surgeries Since Launch in January

New SynergyOLIF360SM Single Position Workflow with Infuse™ Bone Graft

DUBLIN and CHICAGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch of several new procedural solutions for spine surgery, further reinforcing the company’s leadership role in the spine industry. These solutions are part of the company’s market-leading Surgical Synergy platform, which integrates Medtronic technologies intended to create consistent, predictable, and reproducible spine procedures. Medtronic will unveil the new technologies at the North American Spine Society (NASS) 2019 Annual Meeting taking place September 25-28 in Chicago. Medtronic is exhibiting at booths #4611 and #4624.

The launch of these innovative solutions coincides with another milestone as Medtronic also announced that the number of Mazor X Stealth Edition™ patient cases surpassed 1,000 since its commercial launch earlier this year. The system combines preoperative planning software, Stealth™ navigation, and robotic-guidance for pedicle screw placement during spinal procedures.

“The breadth of our portfolio is unparalleled, but what truly sets us apart is our deep expertise and experience. Our technologies have been trusted for the treatment of millions of spine patients – and we’re incredibly proud of that,” said Jacob Paul, senior vice president and president of Medtronic’s Spine division, which is part of the Restorative Therapies Group. “Providing a truly integrated ecosystem of innovative procedural solutions is in our DNA, and it’s how we transform spine outcomes for physicians and their patients.”

Additional details on the Medtronic launches and activities at NASS include:

SynergyOLIF360SM Single-Position Workflow is differentiated with Infuse™ Bone Graft*as well as the combination of O-Arm™ Imaging and Stealth software, which have been trusted in millions of surgeries to date. Integrated technologies enable the entire OLIF (oblique lateral interbody fusion) procedure to be performed while the patient is on his or her side, eliminating the time and cost associated with mid-procedure repositioning.1,2,3,4

  • Surgeon-led educational sessions at booth #4611 for SynergyOLIF360 include:
    • Wednesday, September 25, from 10:00-10:30 a.m.
    • Friday, September 27, from 10:00-10:30 a.m.

Titan Spine Interbody Devices with FiberCel™ Viable Bone Matrix (VBM) combines proprietary Titan nanoLOCK™ Surface Technology, which increases cellular factors related to bone growth and anti-inflammation, with FiberCel VBM. The award-winning Titan nanoLOCK surface technology has undergone strenuous research with several peer-reviewed, in vitro studies driving its development. Titan nanoLOCK is offered across seven different interbody platforms to meet a variety of procedural needs.

  • Surgeon-led educational sessions on Titan Spine technology include:
    • Wednesday, September 25, from 10:00-10:30 a.m. at booth #4624
    • Thursday, September 26, 1:00 p.m., “Biomimicry: How nanoLOCK Leverages Nature to Facilitate Bone Remodeling,” at Gold Theater, NASS Exhibit Hall
    • Thursday, September 26, 6:00-8:00 p.m., Dinner Event: “nanoLOCK Live: The Past, Present, and Future of Nanotechnology in Spine,” at Marriott Marquis Great Lakes Ballroom B. Registration required online or onsite
    • Friday, September 27, from 10:00-10:30 a.m. at booth #4624

SynergyCorpectomySM is the first and only fully-navigated corpectomy system. The workflows feature the new, expandable T2 Stratosphere™ implant, Grafton™ DBM DBF, and the newly-launched Midas Rex™ MR8 System. It is integrated with O-arm and Stealth to enable pre-surgical planning, real-time navigation, and multiple benefits including virtual sizing of the implant, 3-D implant placement visualization, and confirmation of implant placement when using a Surgical Synergy workflow.

Mazor X Stealth Edition is a breakthrough in robotic-assisted spine surgery intended to deliver predictability and flexibility through real-time image guidance informed by integrated, interactive 3-D planning and information systems. The system was designed to promote Surgical Synergy with implants, navigation, imaging, and robotics via one platform that merges industry-leading technologies – Mazor X robotic surgery platform and Stealth navigation technology. The company recently surpassed 1,000 Mazor X Stealth Edition patient cases, achieving a milestone in the treatment of spinal conditions. Medtronic will be expanding the system’s capabilities and further incorporate the system into its procedural workflows.

  • Surgeon-led educational sessions at booth #4611 for Mazor X Stealth Edition include:
    • Wednesday, September 25, from 3:00-3:30p.m.
    • Thursday, September 26, from 3:05-3:35 p.m.

Midas Rex™MR8™ high speed drill system delivers controlled precision, versatile access, and compatibility with Stealth to seamlessly integrate with our spine technologies. Midas Rex has been an industry leader in surgical drills for 57 years.

Additional NASS-sponsored educational opportunities include:

  • “BMP in 2019: The Biologic Hasn’t Changed, but the Evidence Has”
    • Wednesday, September 25, 2:05 p.m., Skyline Ballroom W365c
    • Surgeon-led panel discussion

Analyst and Investor Briefing

Medtronic will host a webcast on Wednesday, September 25, 2019 from 3:30 p.m. to 4:30 p.m. CDT. The webcast will feature remarks from Medtronic RTG management, including comments on Medtronic's strategy and product pipeline. The live audio webcast can be accessed by clicking on the Investor Events link at  on September 25th. Within 24 hours of the webcast, a replay will be available on the same webpage. This event is not part of the official NASS 2019 program.

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

*Approved for use in this procedure in certain sizes of the PEEK Clydesdale™ Implant to treat degenerative disc disease at a single level from L2-L5.

1. As compared to lateral interbody fusion with posterior screw fixation requiring a patient flip.

2. Associated costs may include costs of OR time, personnel, and draping.

3. Ziino, et al. Single position versus lateral-then-prone positioning for lateral interbody fusion and pedicle screw fixation. J Spine Surgery 2018;4(4):717-724.

4. Whitecloud et al. TLIF vs Anterior-Posterior Interbody Fusion of the Lumbar Spine: A Financial Analysis. J Spine Disorders 2001; 14(2):100-103.

Sara Thatcher

Public Relations

Ryan Weispfenning

Investor Relations

Attachment

EN
24/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Medtronic, plc: Key facts and statistics - LTM October 2025

A summary company profile, detailing Medtronic plc’s business operations and financial highlights.

Medtronic Plc: 1 director

A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch